Melanotan Sourcing Vocabulary and Community Research Queries: A Research Review of MT-I and MT-II Melanocortin Receptor Pharmacology, Cyclic Lactam Structure and Catalogue Query Resolution

Reviewed by Peptide Insider Research Desk · October 2026 · 10 min read

Community research forums and catalogue search logs reveal a persistent vocabulary of sourcing-intent queries surrounding the melanotan family of melanocortin receptor agonists. Strings such as "melanotan purchase," "order melanotan," "where to buy melanotan," "melanotan where to buy," "where can i buy melanotan," "melanotan online," "buy melanotan 1 online" and "melanotan ii buy online" recur at measurable search volume alongside orthographic conflations like "melanotanii" and "melanotan ii mt ii." Community-specific labels such as "melanotan 1 reddit," "melanotan ii reddit," "melanotan 1 vs 2 reddit," "melanotan peptide reddit" and "moreplatesmoredates melanotan" further indicate that prospective investigators consult informal peer discourse before evaluating supplier catalogues for terms like "peptide sciences melanotan 2," "melanotan 2 peptide sciences," "peptide melanotan 1," "melanotan express," "melanotan 1 buy," "where to buy melanotan 2 peptide" and "buy melanotan 2 starter kit." This review resolves each query class to its canonical compound identity, maps the melanocortin receptor pharmacology that distinguishes Melanotan I from Melanotan II, and clarifies which catalogue strings fall within research-use-only (RUO) scope versus those that implicate dosing or promotional guidance. All information presented herein is strictly for research reference; not for human or veterinary use.

Melanocortin Receptor Pharmacology: MT-I versus MT-II Selectivity

The pharmacological distinction between Melanotan I and Melanotan II centres on receptor-subtype selectivity, a question that surfaces repeatedly in community queries such as "melanotan 1 vs 2 reddit." Alpha-MSH, the endogenous reference ligand, is a non-selective agonist across MC1R, MC3R, MC4R and MC5R [5]. MT-I was designed to preserve the linear alpha-MSH backbone while incorporating norleucine at position 4 (replacing oxidation-sensitive methionine) to improve chemical stability; the result is a compound that retains preferential MC1R binding and activates the cAMP–PKA–CREB–MITF signalling axis that drives eumelanin biosynthesis [1, 6].

MT-II, by contrast, was engineered by the Hruby laboratory through Asp⁵–Lys¹⁰ lactam cyclisation, which locks the pharmacophore (His-D-Phe-Arg-Trp) into a beta-turn conformation [2, 3]. This constrained geometry increases binding affinity across MC1R through MC5R (excluding MC2R, the ACTH receptor), yielding a pan-melanocortin agonist roughly 1,000-fold more potent than endogenous alpha-MSH in frog-skin bioassays [3]. The non-selectivity of MT-II is the structural basis for its divergent preclinical signal profile: MC1R activation mediates pigmentation, MC3R/MC4R engagement modulates appetite and energy expenditure, and MC4R activation in the paraventricular nucleus underlies pro-erectile effects first documented in human pilot studies [4, 7].

Structural Chemistry and Cyclic Lactam Design

The design of MT-II represents a landmark in peptide medicinal chemistry. The parent sequence Ac-Nle⁴-c[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-NH₂ features a 23-membered lactam ring formed between the side-chain carboxyl of Asp and the epsilon-amino of Lys [2]. Al-Obeidi et al. (1989) demonstrated that this cyclisation converted the flexible linear peptide into a constrained beta-turn, dramatically improving receptor residence time and metabolic half-life compared to linear alpha-MSH analogues [2]. Subsequent work by Hruby et al. (1995) systematically varied ring size and stereochemistry, establishing that the 23-membered Asp–Lys lactam with D-Phe⁷ provided optimal potency across frog-skin and lizard-skin bioassays [3]. The inclusion of D-phenylalanine rather than the native L-isomer was critical: it reoriented the aromatic side chain to complement a hydrophobic pocket within the MC1R transmembrane bundle, increasing binding affinity by approximately two orders of magnitude [3].

More recent structural studies using cryo-electron microscopy have confirmed that both MT-I and MT-II adopt a U-shaped binding pose within the MC1R orthosteric pocket, with the conserved HFRW motif buried in the transmembrane domain [8]. Calcium-assisted ligand recognition at MC1R further modulates binding kinetics, a mechanism now understood to differentiate MC1R from other melanocortin subtypes [8].

Preclinical and Clinical Evidence Table

Query-Orthography Crosswalk and RUO Scope Classification

Catalogue search logs and community forums generate a heterogeneous vocabulary around the melanotan family. The table below classifies each query string by its orthographic class, resolves it to a canonical compound identity, and assigns an RUO scope status. Strings classified as Declined implicate dosing guidance, promotional content, or unresolvable vendor-specific labels that fall outside research-use-only review scope.

MT-I versus MT-II: Structural and Functional Comparison

The query "melanotan 1 vs 2 reddit" and related community comparisons reveal a persistent need to disambiguate these two compounds. MT-I is a linear tridecapeptide (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) that functions as a selective MC1R agonist, with minimal cross-reactivity at MC3R–MC5R at physiological concentrations [1, 6]. Its regulatory trajectory led to approval as afamelanotide (Scenesse) for erythropoietic protoporphyria in both the EMA (2014) and FDA (2019) frameworks [1, 14].

MT-II is a cyclic heptapeptide with pan-melanocortin activity. Its lack of receptor selectivity—binding MC1R, MC3R, MC4R and MC5R with comparable nanomolar affinity—means that preclinical observations include not only pigmentary changes but also appetite suppression (via hypothalamic MC3R/MC4R) and pro-sexual effects (via MC4R in the paraventricular nucleus) [4, 7, 9]. The metabolite bremelanotide (PT-141), derived from MT-II through hydrolytic ring opening, retains MC4R selectivity and was approved by the FDA in 2019 for a separate clinical indication [4].

A critical distinction for research evaluation: MT-I has an established clinical safety dataset spanning over 8 years of observation in 115 EPP patients with no elevated melanoma incidence [10]. MT-II, by contrast, remains investigational, and unregulated use has been associated with eruptive melanocytic naevi and, in rare case reports, melanoma development of uncertain causal attribution [11, 12]. Evans-Brown et al. (2009) surveyed general-population use patterns in the United Kingdom and documented self-reported adverse events including nausea, facial flushing, and injection-site reactions [13].

Sourcing Vocabulary and Catalogue Label Taxonomy

Catalogue queries such as "melanotan purchase," "melanotan online," "buy melanotan 2 starter kit" and "melanotan express" reflect investigator intent to procure reference-grade material for in vitro or preclinical protocols. When evaluating supplier catalogues, researchers should verify: (a) certificate of analysis (CoA) with HPLC purity report (typically ≥98% for research-grade material), (b) mass-spectrometry confirmation of molecular identity (expected [M+H]⁺ = 1024.2 for MT-II), (c) endotoxin assay (LAL, less than 0.1 EU/mg) for any injectable-format use in animal models, and (d) CAS number concordance (75921-69-6 for MT-I; 121062-08-6 for MT-II) [14].

Queries like "peptide sciences melanotan 2" and "melanotan 2 peptide sciences" represent vendor-specific catalogue lookups. The orthographic variant "melanotanii" appears in search logs as a whitespace-collapsed form of "melanotan II," while "melanotan ii mt ii" represents an abbreviation-expansion pattern where the searcher includes both the full name and abbreviated form. Community-attributed labels such as "moreplatesmoredates melanotan" index influencer-mediated discourse that directs searchers toward the peptide class without specifying subtype.

Frequently Asked Questions

What is the difference between melanotan 1 vs 2 as discussed on reddit forums?

Melanotan I (afamelanotide) is a linear, MC1R-selective alpha-MSH analogue (CAS 75921-69-6) that has an established regulatory pathway and a multi-year clinical safety record in erythropoietic protoporphyria [1, 10]. Melanotan II is a cyclic lactam heptapeptide (CAS 121062-08-6) with pan-melanocortin activity at MC1R, MC3R, MC4R and MC5R; it remains investigational and has been associated in case reports with eruptive melanocytic naevi [3, 12]. Community forums (e.g., "melanotan 1 reddit," "melanotan ii reddit," "melanotan peptide reddit") frequently discuss this distinction but do not constitute peer-reviewed evidence.

Where can researchers source melanotan for in vitro studies?

Queries such as "where to buy melanotan," "where can i buy melanotan," "melanotan where to buy," "where to buy melanotan 2 peptide" and "melanotan 1 buy" indicate sourcing intent. Researchers should confirm analytical purity (≥98% by HPLC), CAS concordance and endotoxin clearance on the supplier certificate of analysis before incorporating any material into preclinical protocols. This review does not recommend, endorse, or rank any vendor.

What does melanotan ii mt ii mean as a search term?

The query "melanotan ii mt ii" is an abbreviation-expansion pattern in which the searcher redundantly includes both the full Roman-numeral name (melanotan II) and its standard abbreviation (MT-II). The whitespace-collapsed variant "melanotanii" similarly resolves to Melanotan II (CAS 121062-08-6; MW 1024.2 Da) [2, 3].

Why do searches like buy melanotan 2 starter kit appear in catalogue logs?

The query "buy melanotan 2 starter kit" reflects a bundled-procurement pattern where the searcher intends to acquire the peptide alongside reconstitution accessories (bacteriostatic water, syringes, sterile vials). Such kits are catalogue constructs; the peptide itself (MT-II, CAS 121062-08-6) requires standard reconstitution with appropriate solvent for the intended assay [14].

Does this review provide melanotan 1 dosing recommendation information?

No. Queries such as "melanotan 1 dosing recommendation" and "melanotan 1 10mg dosage" request dosing guidance that falls outside research-use-only scope. These strings are classified as Declined-dosage-guidance in the crosswalk above. Published clinical pharmacokinetic parameters for afamelanotide are available in the peer-reviewed literature (Minder, 2017; PMID 28063031) [14], but this review does not interpret or relay dosing protocols.

Where to Source Melanotan Peptides for Research

Investigators evaluating catalogue listings for melanotan reference material—whether prompted by queries such as "order melanotan," "melanotan purchase," "melanotan online" or "buy melanotan 1 online"—should confirm analytical documentation before placing orders. Research-grade melanotan peptides are available from established suppliers including Short Chain Aminos, which maintains comprehensive CoA documentation for its melanocortin-agonist catalogue, as well as BioPep for bulk-format research quantities. Additional sourcing options include Catalyst Research and Apex Research Services, both of which list MT-I and MT-II reference standards with accompanying mass-spectrometry identity confirmation. No vendor is assessed or endorsed by this review; investigators should independently verify purity, identity and endotoxin documentation for their specific protocol requirements.

Works Cited

1. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. PMID: 26132941.
2. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-2561. PMID: 2555512.
3. Hruby VJ, Lu D, Sharma SD, et al. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-MSH-(4-10)-NH2. J Med Chem. 1995;38(18):3454-3461. PMID: 7658432.
4. Wessells H, Fuciarelli K, Hansen J, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-S79. PMID: 11035391.
5. Hadley ME. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16412534.
6. Ugwu SO, Blanchard J, Bhardwaj R, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18(9):811-816. PMID: 9113347.
7. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. PMID: 8637402.
8. Liu H, Yan K, Yuan L, et al. Molecular mechanism of melanocortin receptor recognition. Cell Discov. 2023;9:83. doi: 10.1038/s41421-023-00586-4.
9. Eliason NL, Bhatt R, Mahler SV. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding. Neuropeptides. 2022;96:102285. PMID: 36155088.
10. Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. PMID: 25494545.
11. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. PMID: 28266027.
12. Paurobally D, Baker R. Melanotan-associated melanoma. Br J Dermatol. 2011;164(6):1403-1404. PMID: 21564053.
13. Evans-Brown M, McVeigh J, Perkins C, Bellis MA. Use of melanotan I and II in the general population. BMJ. 2009;338:b566. PMID: 19224885.
14. Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815-823. PMID: 28063031.
15. Sweeney P, Bedenbaugh MN, Cone RD, et al. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol. 2023;19(9):507-519. PMID: 37365323.

This article is provided strictly for research reference; not for human or veterinary use. No vendor is assessed or endorsed. Investigators must independently verify compound identity, purity and regulatory status for their jurisdiction before initiating any protocol.